Health TrialsbyHealthPanel

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

ConditionDiabetes Mellitus, Type 2
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorEli Lilly and Company

About this trial

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Have type 2 diabetes

Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening

Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive

Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Disqualifiers

Have type 1 diabetes

Trial design

Design model

Parallel

Treatments tested in this trial

  • LY3938577

    Drug

    Administered SC

  • Degludec

    Drug

    Administered SC

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: LY3938577Experimental treatment 1 intervention
Group B: DegludecActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)

Time frame
Baseline through Week 20

Secondary outcomes

1

Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Superiority Analysis)

Time frame
Baseline through Week 20
2

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame
Baseline, Week 20
3

Pharmacokinetics (PK): Average Concentration of LY3938577

Time frame
Baseline through Week 20

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov
Apply now